We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rezolute Inc | NASDAQ:RZLT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.21 | 7.61% | 2.97 | 2.82 | 3.04 | 3.094 | 2.77 | 2.77 | 127,106 | 23:08:36 |
“This quarter marked steady progress as we continue to drive our clinical programs forward, including RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “With the $130 million financing that we completed, we are well-capitalized to advance RZ358 into a Phase 3 trial and to initiate a Phase 2 proof-of-concept study for RZ402. We believe these candidates hold the potential to create a new standard of care for patient populations in need of better therapeutic options.”
Corporate and Clinical Highlights
Fourth Quarter and Full Year Fiscal 2022 Financial Results
About Rezolute, Inc.Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, the treating physician, and the healthcare system. Patient, clinician, and advocate voices are integrated in the Company’s drug development process, enabling Rezolute to boldly address a range of severe conditions. Rezolute is steadfast in its mission to create profound, positive, and lasting impact on patients’ lives. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism, a rare pediatric endocrine disorder. Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. For more information, visit www.rezolutebio.com or follow us on Twitter.
Forward-Looking StatementsThis release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in Rezolute’s filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Investor Contact:Kimberly Minarovich/Carrie McKimArgot Partnersrezolute@argotpartners.com 212-600-1902
Media:Ingrid MezoCanale Communications, Inc.ingrid.mezo@canalecomm.com 301-473-2881
Rezolute, Inc. | ||||||||||||||||
Condensed Consolidated Financial Statements Data | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Condensed Consolidated Statements of Operations Data: | ||||||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 8,574 | $ | 4,389 | $ | 32,486 | $ | 14,987 | ||||||||
General and administrative | 2,725 | 2,247 | 9,357 | 7,907 | ||||||||||||
Total operating expenses | 11,299 | 6,636 | 41,843 | 22,894 | ||||||||||||
Loss from operations | (11,299 | ) | (6,636 | ) | (41,843 | ) | (22,894 | ) | ||||||||
Non-operating income, net | 1,876 | 146 | 783 | 1,992 | ||||||||||||
Net loss | $ | (9,423 | ) | $ | (6,490 | ) | $ | (41,060 | ) | $ | (20,902 | ) | ||||
Net loss per common share | ||||||||||||||||
Basic | $ | (0.30 | ) | $ | (0.78 | ) | $ | (2.26 | ) | $ | (2.72 | ) | ||||
Diluted | $ | (0.37 | ) | $ | (0.78 | ) | $ | (2.32 | ) | $ | (2.72 | ) | ||||
Weighted average number of common shares outstanding: | ||||||||||||||||
Basic | 31,429 | 8,352 | 18,197 | 7,671 | ||||||||||||
Diluted | 36,302 | 8,352 | 19,487 | 7,671 | ||||||||||||
June 30, | June 30, | |||||||||||||||
2022 | 2021 | |||||||||||||||
Condensed Consolidated Balance Sheets Data: | ||||||||||||||||
Cash and cash equivalents | $ | 150,410 | $ | 41,047 | ||||||||||||
Working capital | 149,642 | 40,025 | ||||||||||||||
Total assets | 152,420 | 42,609 | ||||||||||||||
Long term debt, net of discount | — | 13,968 | ||||||||||||||
Accumulated deficit | (209,198 | ) | (168,138 | ) | ||||||||||||
Total stockholders’ equity | 149,471 | 26,099 | ||||||||||||||
1 Year Rezolute Chart |
1 Month Rezolute Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions